INTRODUCTION {#s1}
============

Despite the obvious improvements in the early diagnosis and treatment of cancer, cancer remains amajor worldwide public health burden in recent year, with approximately 1,688,780 new cases and 600,920 new deaths in the United States in 2017 \[[@R1]\]. Cancer is a multi-step complex and multifactorial disease involving the intricate interactions between numerous genetic as well as environmental risk factors, such as age, race, lifestyle, obesity, family history, smoking status and endocrine system \[[@R2]--[@R4]\]. It is well known that various genes are associated with the carcinogenesis due to the polygenic inheritanc of cancer \[[@R5]\]. However, the exact mechanism of cancer is unclear and remains to be identified. Multiple studies have shown that the screening and identification of single-nucleotide polymorphisms (SNPs) as a predicted biomarker of human genetic variation might affect individual in the sensitivity to cancer risk and therapeutic responses in early cancer patients. Therefore, it has been demonstrated that SNPs may play an important role in high susceptibility for cancer to discover novel loci or genes \[[@R6]\].

As a LY-6/Thy-1 family of cell surface antigens, prostate stem cell antigen (PSCA) gene is located on chromosome 8q24.2 containing 464 SNPs, and the PSCA protein is a 123-amino-acid cell membrane glycoprotein, which encodes a PSCA protein that is reported as a cell surface marker \[[@R7]\]. Compared to the normal tissues, PSCA is further up-regulated in prostate cancer tissue, and which is also found in several other cancers, including pancreatic cancer and gallbladder cancer \[[@R8]--[@R10]\]. Moreover, as the most extensively studied SNPs in the PSCA gene, rs2294008 C\>T and rs2976392 G\>A are shown to be associated with increased risk of bladder and stomach cancers \[[@R11], [@R12]\]. However, there is no obvious evidence for the role of PSCA in carcinogenesis. Thus, it was hypothesized that PSCA gene polymorphisms were likely to play an vital role in carcinogenesis.

In recent years, several studies have been widely investigated the possible association between the PSCA polymorphisms and risk of cancer. For instance, Qiu et al. \[[@R13]\] demonstrated that the PSCA rs2294008 T alleles was risk factors for gastric cancer in this eastern Chinese population. However, Mou et al. \[[@R19]\] found that PSCA rs2294008 polymorphism possessed no difference/association with gastric cancer risk among cases and controls. Hence, we cannot definitively declare that the observed association between PSCA polymorphisms and risk of cancer. So, we aimed to conduct a meta-analysis including all accessible case-control studies to reconcile all the discordant results to systematically clarify the role of these SNPs in susceptibility to cancer. Additionally, lack of further research in trial sequential analysis (TSA) prevented comprehensive understanding of the association between PSCA polymorphisms and cancer susceptibility in some previous meta-analyses. Hence, with this in mind, we conducted the present meta-analysis and TSA to critically evaluate the association between PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms and cancer risk and clarify whether the evidence for the results was sufficient.

RESULTS {#s2}
=======

Studies characteristics {#s2_1}
-----------------------

A total of 41 case-control studies were found to fulfill the eligibility criteria for the current meta-analysis of the PSCA rs2294008 and rs2976392 with cancer risk including 34,764 patients and 43,309 controls \[[@R11]--[@R48]\], and the detailed characteristics of individual studies included were listed in Table [1](#T1){ref-type="table"}. Besides, the distribution of genotypes in the controls was consistent between Hardy-Weinberg equilibrium (HWE) in all involved studies except two articles \[[@R13], [@R37]\]. Figure [1](#F1){ref-type="fig"} showed the flowchart of literature search and selection process.

###### Characteristics of individual studies included in the meta-analysis

  PSCA       rs2294008                                                                                          Case(n)   Control(n)                                   
  ---------- ----------------- --------------- ----------- ----- ------------ ---------------- ------ --------- --------- ------------ ------ ------ ------ ------ --- -----
  2016       Qiu               China           Asian       HB    Taqman       Gastric          1124   1192      537       489          98     663    383    146    8   N
  2016       Wang              China           Asian       HB    Sequenom     Breast           560    583       273       231          56     299    247    37     8   Y
  2016       Wang              China           Asian       HB    Taqman       Cervical         1126   1237      609       469          48     618    527    92     9   Y
  2015       Garcia-Gonzalez   Spain           Caucasian   HB    Taqman       Gastric          603    675       154       302          147    199    346    130    9   Y
  2015       Ichikawa          Japan           Asian       HB    PCR-RFLP     Gastric          193    266       24        104          65     52     119    95     7   Y
  2015       Sun               China           Asian       HB    Taqman       Gastric          692    774       322       309          61     405    297    72     9   Y
  2015       Kupcinskas        Latvia          Caucasian   HB    Taqman       Colorectal       191    377       60        77           54     100    189    88     7   Y
  2015       Zhang             China           Asian       HB    Sequenom     Gastric          475    480       227       207          41     261    183    36     8   Y
  2015       Mou               China           Asian       PB    DHPLC        Gastric          198    130       23        126          49     5      34     91     9   Y
  2014       Kupcinskas        Lithuania       Caucasian   HB    Taqman       Gastric          251    243       33        116          102    64     123    56     8   Y
  2014       Lee               Korea           Asian       HB    HRM          Bladder          411    1700      70        222          119    414    818    468    9   Y
  2014       Wang              China           Asian       PB    Taqman       Bladder          1210   1008      604       509          97     566    376    66     9   Y
  2014       Sun               USA             Caucasian   HB    Taqman       Gastric          130    125       17        64           49     30     63     32     9   Y
  2014       Dai               China           Asian       PB    Taqman       Esophageal       2083   2220      1232      724          127    1222   851    147    9   Y
  2013       Zhao              China           Asian       PB    DHPLC        Gastric          717    951       275       342          100    465    401    85     8   Y
  2013       Rizzato           Germany         Caucasian   PB    Taqman       Gastric          178    1057      23        86           69     231    507    319    9   Y
  2013       Rai               India           Asian       HB    Taqman       Gallbladder      405    247       104       233          68     79     126    42     7   Y
  2013       Ono               Japan           Asian       HB    Taqman       Gallbladder      44     173       9         23           12     30     75     68     8   Y
  2013       Ma                China           Asian       PB    MassARRAY    Bladder          175    962       84        80           11     543    355    64     9   Y
  2012       Smith             Scotland        Caucasian   HB    Taqman       Colorectal       77     804       25        39           13     287    387    130    7   Y
  2012       Sala              European        Caucasian   PB    Taqman       Gastric          409    1515      93        198          118    491    714    310    9   Y
  2012       Li                China           Asian       PB    MassARRAY    Gastric          300    300       124       141          35     168    111    21     8   Y
  2012       Kim               Korea           Asian       HB    MassARRAY    Breast           451    459       119       216          116    113    240    106    8   Y
  2012       Fu                European &USA   Caucasian   PB    GWAS         Bladder          5393   7324      1363      2804         1226   2107   3645   1572   9   Y
  2011       Zeng              China           Asian       HB    PCR-RFLP     Gastric          460    549       202       216          42     289    223    37     8   Y
  2011       Song              Korea           Asian       HB    PCR-RFLP     Gastric          3245   1700      576       1620         1049   414    818    468    9   Y
  2011       Lochhead          USA             Caucasian   PB    Taqman       Esophageal       158    208       61        63           34     49     110    49     9   Y
  2011       Lochhead          USA             Caucasian   PB    Taqman       Gastric          308    208       85        129          94     49     110    49     9   Y
  2011       Lochhead          Poland          Caucasian   PB    Taqman       Gastric          292    382       47        143          102    101    166    115    8   N
  2011       Joung             Korea           Asian       HB    MassARRAY    Prostate         192    168       45        98           49     47     84     37     9   Y
  2010       Wang              China           Asian       HB    PCR-RFLP     Bladder          581    580       272       259          50     316    220    44     7   Y
  2010       Ou                China           Asian       HB    PCR/LDR      Gastric          196    246       85        93           18     132    96     18     8   Y
  2010       Lu                China           Asian       PB    PCR-RFLP     Gastric          1023   1069      547       404          72     605    387    77     8   Y
  2009       Wu                European&USA    Caucasian   HB    GWAS         Bladder          5038   9363      1288      2613         1137   2842   4668   1853   9   Y
  2009       Wu                China           Asian       PB    PCR-RFLP     Gastric          1710   995       759       819          132    506    412    77     9   Y
  2009       Matsuo            Japan           Asian       HB    Taqman       Gastric          708    708       330       329          49     273    338    97     8   Y
  2008       Sakamoto          Korea           Asian       HB    Taqman       Gastric          871    390       133       461          277    122    176    92     7   Y
  2008       Sakamoto          Japan           Asian       HB    GWAS         Gastric          1524   1396      96        700          728    210    650    536    9   Y
  **PSCA**   **rs2976392**                                                                                                                                             
  Year       Surname           Country         Ethnicity   SOC   Genotyping   Type of Cancer   Case   Control   GG        GA           AA     GG     GA     AA         HWE
  2016       Qiu               China           Asian       HB    Taqman       Gastric          1124   1192      535       488          101    682    388    122    8   N
  2016       Wang              China           Asian       HB    Sequenom     Breast           560    583       287       230          43     298    247    38     8   Y
  2015       Kupcinskas        Latvia          Caucasian   HB    Taqman       Colorectal       191    364       56        84           51     99     180    85     7   Y
  2015       Sun               China           Asian       HB    Taqman       Gastric          692    774       319       308          65     403    299    72     9   Y
  2015       Zhang             China           Asian       HB    Sequenom     Gastric          436    451       190       208          38     231    184    36     8   Y
  2014       Kupcinskas        Lithuania       Caucasian   HB    Taqman       Gastric          249    232       34        113          102    62     116    54     8   Y
  2014       Wang              China           Asian       HB    Taqman       Gastric          283    275       131       134          18     149    108    18     9   Y
  2013       Ju                China           Asian       HB    sequencing   Gastric          155    210       67        65           23     107    87     16     8   Y
  2013       Ono               Japan           Asian       HB    Taqman       Gallbladder      44     173       9         23           12     29     76     68     8   Y
  2012       Kim               Korea           Asian       HB    MassARRAY    Breast           453    460       121       217          115    115    239    106    8   Y
  2011       Shen              China           Asian       PB    DHPLC        Gastric          60     60        24        31           5      29     26     5      9   Y
  2011       Joung             Korea           Asian       HB    MassARRAY    Prostate         194    168       45        100          49     46     85     37     9   Y
  2010       Ou                China           Asian       HB    PCR/LDR      Gastric          196    246       99        85           12     130    102    14     8   Y
  2010       Lu                China           Asian       PB    PCR-RFLP     Gastric          1043   1082      500       464          79     602    402    78     8   Y
  2009       Wu                China           Asian       PB    PCR-RFLP     Gastric          1724   1002      789       793          142    492    429    81     9   Y
  2009       Matsuo            Japan           Asian       HB    Taqman       Gastric          707    707       331       328          48     274    337    96     8   Y
  2008       Sakamoto          Korea           Asian       HB    Taqman       Gastric          865    390       134       453          278    122    175    93     7   Y
  2008       Sakamoto          Japan           Asian       HB    GWAS         Gastric          1525   1397      97        691          737    211    650    536    9   Y

SOC: source of control; HB: hospital-based controls; PB: population-based controls;

NOS: Newcastle-Ottawa Scale; HWE: Hardy-Weinberg equilibrium.

![Flowchart of literature search and selection process](oncotarget-08-51766-g001){#F1}

For the PSCA rs2294008 polymorphism, 38 studies were performed on investigating the association between this SNP with susceptibility of cancer, including 34,266 cases and 42,764 controls \[[@R11]--[@R45]\]. In these studies, there were 26 studies of Asian populations and the other 12 studies were Caucasian ethnicity. The studied type of cancer included gastric cancer, breast cancer, cervical cancer, colorectal cancer, bladder cancer, esophageal cancer, gallbladder cancer and prostate cancer. Besides, seven genotyping methods were applied, such as Taqman, Sequenom, PCR-RFLP, DHPLC, HRM, GWAS and PCR/LDR. Furthermore, we divided them into population-based group or hospital-based group in all studies to distinguish between different sources of control group. Similarly, for the PSCA rs2976392 polymorphism, there were 18 studies exploring the relationship between this polymorphism and risk of overall cancer with 10,501 cases and 9,766 controls \[[@R12]--[@R14], [@R18], [@R20]--[@R21], [@R23], [@R28], [@R32], [@R36], [@R40]--[@R41], [@R43]--[@R44], [@R46]--[@R48]\]. In regard to source of control, the studies consisted of 3 population-based controls and 15 hospital-based controls. Moreover, there were 16 Asian populations and 2 Caucasian populations. In addition, the studied cancer type included gastric cancer, prostate cancer, colorectal cancer, breast cancer, and gallbladder cancer.

Quantitative synthesis results {#s2_2}
------------------------------

The main results of this meta-analysis of the associations between PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms and risk of cancer were showed in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Overall, our results indicated that PSCA rs2294008 C\>T polymorphism was associated with an increased risk of cancer (*dominant model*: pooled OR=1.28, 95% CI: 1.17--1.41; *recessive model*: pooled OR=1.10, 95% CI: 0.99--1.22; *homozygote model*: pooled OR=1.30 95% CI: 1.14--1.48; *heterozygote model*: pooled OR=1.27, 95% CI: 1.14--1.48; *allele model*: pooled OR=1.15, 95% CI: 1.08--1.22) in the random-effects model. When stratified by type of cancer, the results showed PSCA rs2294008 had significantly increased risk of gastric cancer (*dominant model*: pooled OR = 1.45, 95% CI: 1.27--1.66; *recessive model*: pooled OR = 1.14, 95% CI: 0.95--1.36; *homozygote model*: pooled OR = 1.46 95% CI: 1.17--1.83; *heterozygote model*: pooled OR = 1.43, 95% CI: 1.27--1.60; *allele model*: pooled OR = 1.22, 95% CI: 1.10--1.35) and bladder cancer (*dominant model*: pooled OR = 1.26, 95% CI: 1.19--1.32; *recessive model*: pooled OR = 1.18, 95% CI: 1.07--1.19; *homozygote model*: pooled OR=1.29 95% CI: 1.21--1.38; *heterozygote model*: pooled OR=1.25, 95% CI: 1.18--1.32; *allele model*: pooled OR=1.14, 95% CI: 1.07--1.19) (Figure [2](#F2){ref-type="fig"}). Besides, the stratification analyses by ethnicity found that the results were significant in Asian and Caucasian populations. What\'s more, in the subgroup analysis by source of controls, carriers of T allele in PSCA rs2294008 were a strong risk factor of cancer in both population-based controls and hospital-based controls.

![Forest plots of the association between PSCA rs2294008 C\>T polymorphism and cancer susceptibility in the stratification analyses by type of cancer\
(**A**) dominant model; (**B**) recessive model; (**C**) homozygous model; (**D**) heterozygous model; (**E**) allele model.](oncotarget-08-51766-g002){#F2}

In the PSCA rs2976392 polymorphism, we found this polymorphism was significantly associated with risk of cancer (*dominant model*: pooled OR=1.30, 95% CI: 1.11--1.53; *recessive model*: pooled OR=1.12, 95% CI: 0.94--1.33; *homozygote model*: pooled OR=1.30 95% CI: 0.99--1.70; *heterozygote model*: pooled OR=1.28, 95% CI: 1.11--1.49; *allele model*: pooled OR=1.17, 95% CI: 1.05--1.31). Stratification analyses by type of cancer also detected that rs2976392 polymorphism increased cancer risk only in gastric cancer (*dominant model*: pooled OR=1.43, 95% CI: 1.18--1.74; *recessive model*: pooled OR=1.14, 95% CI: 0.91--1.43; *homozygote model*: pooled OR=1.41 95% CI: 1.23--1.61; *heterozygote model*: pooled OR=1.41, 95% CI: 1.19--1.67; *allele model*: pooled OR=1.24, 95% CI: 1.08--1.41) (Figure [3](#F3){ref-type="fig"}). Moreover, in the stratification analyses by ethnicity, the significant results were only in Asian populations (*dominant model*: pooled OR=1.29, 95% CI: 1.09--1.53; *recessive model*: pooled OR=1.06, 95% CI: 0.89--1.27; *homozygote model*: pooled OR=1.24 95% CI: 0.93--1.64; *heterozygote model*: pooled OR=1.29, 95% CI: 1.11--1.51; *allele model*: pooled OR=1.15, 95% CI: 1.03--1.29). Lastly, increased cancer susceptibility associated with PSCA rs2976392 was also observed in population-based and hospital-based studies.

![Forest plots of the association between PSCA rs2976392 G\>A polymorphism and cancer susceptibility in the stratification analyses by type of cancer\
(**A**) dominant model; (**B**) recessive model; (**C**) homozygous model; (**D**) heterozygous model; (**E**) allele model.](oncotarget-08-51766-g003){#F3}

Sensitivity analysis {#s2_3}
--------------------

Sensitivity analysis was carried out to distinguish their influence of each individual study on the combined values by repeating the meta-analysis through sequentially deleting the single studies study each time. The sensitivity analysis of associations for PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms with the risk of cancer in five types of models (dominant model, recessive model, homozygous model, heterozygous model and allele model) was listed in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}, which demonstrated stability and reliability of results for such associations.

Publication bias {#s2_4}
----------------

We assessed the potential publication bias for the all available data by the Begg\'s funnel plot and Egger\'s test and the results were shown in Figure [4](#F4){ref-type="fig"}. No symmetric distribution was seemed in the shapes of the funnel plots for the dominant model, indicating no evidence of significant publication bias, which was also confirmed using Egger\'s test (rs2294008 C\>T: *P* = 0.423; rs2976392 G\>A: *P* = 0.842).

![Begg\'s funnel plot of publication bias test in dominant model\
(**A**) PSCA rs2294008 C\>T polymorphism; (**B**) PSCA rs2976392 G\>A polymorphism.](oncotarget-08-51766-g004){#F4}

Trial sequential analysis results {#s2_5}
---------------------------------

Subsequently, the cumulative Z-curve exceeded the monitoring boundaries and the information size in the PSCA rs2294008 polymorphism by TSA, suggesting sufficient evidence of such association. In addition, the results in the PSCA rs2976392 polymorphism were proved to be solid with sufficient evidence, because of exceeding the trial sequential monitoring boundary. As a result, this findings revealed PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms were strongly associated with cancer risk (Figure [5](#F5){ref-type="fig"}).

![Trial sequential analysis of the association between PSCA polymorphisms and the risk of cancer\
The required information size was calculated based on a two side α = 5%, β = 20%, and a 95% confidence intervals. (**A**) PSCA rs2294008 C\>T polymorphism; (**B**) PSCA rs2976392 G\>A polymorphism.](oncotarget-08-51766-g005){#F5}

DISCUSSION {#s3}
==========

The PSCA gene belongs to a member of Ly-6/Thy-1 family of glycosylphosphatidyl-inositol (GPI)-anchored cell-surface proteins and plays a critical role in multiple cellular events, including cell adhesion, proliferation, and survival \[[@R7]\]. The over-expression of PSCA was initially reported in prostate cancer \[[@R36]\]. Besides, its high-expression is significantly associated with poor prognosis including seminal vesicle invasion, capsular involvement and Gleason score \[[@R49]\]. Therefore, PSCA has been considered as a biomarker of diagnosis and prognosis, as well as a target of therapy for prostate cancer. Moreover, some solid cancer including ovarian mucinous tumor, pancreatic cancer, renal cell carcinoma and bladder cancer have also existed the expression of PSCA \[[@R50]\]. In contrast with observations in prostate cancer, PSCA expression is down-regulated in several cancers, such as gastric cancer, bladder cancer, and gallbladder carcinoma \[[@R13]\]. Morover, PSCA may have tumor-suppressing function in the gastric epithelium in these specific type of cancers.

Previous studies have investigated the associations of PSCA polymorphisms with various cancer susceptibility \[[@R51]--[@R53]\]. For instance, Chandra et al. \[[@R52]\] demonstrated that the PSCA polymorphisms was risk factors for cancer in Asian Population. Besides, Gao et al. \[[@R53]\] found that PSCA rs2294008 polymorphism possessed association with bladder cancer risk. Nevertheless, these results are discrepant and even conflicting. A possible reason arised from the differences in study design, sample size, source of controls, race and genotyping method. All these contributed to the limited statistical power in the published studies. Hence, as we included more studies about the associations between PSCA polymorphisms and the risk of cancer, this meta-analysis was carried out to provide more reliable conclusion to reveal the real associations compared the previous meta-analyses \[[@R51]\]. Furthermore, TSA was used to clarify whether the evidence for the results was sufficient.

As a powerful tool, meta-analysis can provide more sufficient results compared to a single study especially in analyzing unexplained studies \[[@R54]\]. As a result, we suggested there existed a much stronger advantage to prove the association between PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms with the susceptibility to cancer. On the one hand, further researches in different stratified analysis were necessary in these meta-analyses. On the other hand, we for the first time applied TSA to reduce the risk of type I error and testify whether the evidence of our results was reliable. The results suggested that significantly elevated cancer risk was associated with the PSCA rs2294008 C\>T polymorphism levels, particularly in patients with gastric cancer and bladder cancer. Meanwhile, PSCA rs2976392 G\>A polymorphism significantly increased cancer risk only in gastric cancer.

After stratified analysis by type of cancer, the results showed PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms statistically increased cancer risk, especially in gastric cancer and bladder cancer instead of breast cancer, cervical cancer, colorectal cancer and other cancers. Different kinds of cancer have specific characteristic of diverse aspects, which might lead to different statistical results. In addition, the different type of cancer has distinctive polymorphism sites. Therefore, only specific polymorphism site might be associated with a certain type of tumor.

These findings of subgroup analyses based on ethnicity and source of control can be explained as follows. In the subgroup analysis by ethnicity, significantly increased cancer risk was shown in Asian and Caucasian populations in PSCA rs2294008 C\>T polymorphism. Besides, PSCA rs2976392 G\>A polymorphism increased risk of cancer only in Asian populations. Though the exact mechanism was unclear, it was possible that different ethnic groups with various genetic backgrounds might have different SNPs in the developing of cancer. Meanwhile, it is important to meet the unified enrollment criteria and select larger sample size studies, which could make the results more reliable. In addition, we conducted stratified analysis by source of controls and the result was detected significantly both in population-based and hospital-based populations. In this meta-analysis, the results were in concordance with these hypotheses of previous studies, which needed to further prove that PSCA rs2294008 and rs2976392 played an important role in cancer susceptibility as far as possible in all relevant articles published in the future.

As an useful approach, TSA is introduced to calculate the required information size for this meta-analysis with the adaptation of monitoring boundaries, in order to reduce the risk of type I error \[[@R55]--[@R57]\]. Besides, we took advantage of TSA with all included trials to estimate whether a sufficient level of evidence had been reached and whether further trials were necessary \[[@R58]--[@R60]\]. When a *P* value is sufficiently small to show the anticipated effect, it is believed that the application of TSA shows the potential to be more reliable compared to the traditional meta-analysis. For findings of risk of cancer in PSCA rs2294008 C\>T polymorphism, the cumulative Z-curve crossed not only the monitoring boundaries but also the sufficient information size, suggesting that additional new clinical trial should not be needed. Moreover, for results of risk of cancer in PSCA rs2976392 G\>A polymorphism, the cumulative Z-curve not exceeding the required sample size crossed the trial sequential monitoring boundaries, which indicated that our conclusion had reached a sufficient level of evidence \[[@R61],[@R62]\]. In consequence, it was strongly of the view that our results in the current meta-analysis were based on firm evidence of effect, and no further studies was needed to investigate such associations.

Although the overall robust statistical evidence including the implementation of TSA was to estimate a slight association by this meta-analysis, some limitations of this meta-analysis should be taken into consideration when interpreting the present results. Firstly, some published studies involved in the PSCA polymorphisms are not accord with the HWE, resulting in potential bias during control selection or genotyping errors. Secondly, because of existing significant heterogeneity in this meta-analysis, it was very likely the results were interpreted. Thirdly, the effect of multiple confounders such as age, gender, life-style may also play an important role in the development of cancer, but we could not make these subgroup analysis due to insufficient data on the basis of these factors. What\'s more, as a multi-factorial disease, the pathogenesis of cancer is closely related complex interactions between a variety of genetic factors and environmental backgrounds, suggesting risk of cancer would not be influenced by any single gene. Therefore, more new-designed studies about exploring the risk effects of these two SNPs in susceptibility to cancer needed to be further validated in subsequent studies. Accordingly, it is required that more studies be conducted to provide a more definitive conclusion.

MATERIALS AND METHODS {#s4}
=====================

A comprehensive literature search was systematically conducted using the electronic databases PubMed, EMBASE and Web of Science for potential relevant studies, which investigated the association between PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms and risk of cancer, covering all the papers published until September 1st, 2016. The combinations of the following keywords were used: "prostate stem cell antigen", "PSCA polymorphisms", "rs2294008" or "rs2976392", and "gene", "variant", "polymorphism" or "mutation", and "caner", "carcinoma" or "neoplasms". Eligible literatures were retrieved from all publications. Besides, additional literature was further collected manually from reference lists of reviews to make sure all potential eligible publications. Moreover, if studies had partly familiar or overlapping subjects, only the latest or largest sample size was adopted in this meta-analysis.

Inclusion and exclusion criteria {#s4_1}
--------------------------------

Studies were included if they met the inclusion criteria as follows: (1) a case-control or cohort design; (2) investigate or report the relationship between PSCA polymorphisms and cancer susceptibility; (3) sufficient genotype frequency data provided to calculate the odds ratio (OR) and 95% confidence interval (CI). In addition, the major excluding criterion was as follows: (1) no relevant genotype frequency data or overlapping data; (2) reviews or conference abstracts; (3) no case-control studies; (4) providing duplicates of previous publication with others.

Data extraction {#s4_2}
---------------

According to the eligibility criteria, data were extracted from each manuscript independently by two investigators (Qin ZQ and Tang JY). Besides, any disagreement would be solved by a discussion with a third investigator (Li X) to reach a consensus on all the extracted information. From each article, first author\'s name, year of publication, country, ethnicity, source of controls (population-based or hospital-based), genotyping method, type of cancer, sample size of cases and controls, frequency of PSCA rs2294008 and rs2976392 gene polymorphisms in cases and controls respectively, and the results of the HWE test were recorded in a standardized form.

Quality assessment {#s4_3}
------------------

The quality of the studies was assessed using the validated Newcastle-Ottawa Scale (NOS) for nonrandomized studies, including case-control and cohort studies. Separate NOS scales were developed for cohort and case-control studies. It has not been published in peer-reviewed journals so far, although NOS has been widely utilized. NOS awards eight points to each case-control study (four for quality of selection, one for comparability, and three for quality of exposure). A study can be awarded a maximum of one star for each point within the selection and exposure categories, and a maximum of two stars can be given for comparability. Besides, NOS also awards eight points to each cohort study (four for quality of selection, one for comparability, and three for quality of outcome). A study can be awarded a maximum of one star for each point within the selection and outcome categories, and a maximum of two stars can be given for comparability. We considered studies with scores of more than 7 as high-quality studies, and those with scores of 7 or less as low-quality studies.

Statistical analysis {#s4_4}
--------------------

The crude odds ratios (ORs) with 95% confidence intervals (CIs) were measured to evaluate the strength of association between the PSCA rs2294008 and rs2976392 gene polymorphisms with overall cancer susceptibility under these five genetic comparison models: dominant model, recessive model, homozygous model, heterozygous model and allele model, based on the genotype frequency distribution in cases and controls. An OR value \> 1 indicated a significantly increased cancer risk, while an OR value \< 1 stood for more benefit in risk of cancer. The goodness-of-fit chi-square test was adopted to check HWE among controls, and the deviation was regarded significant disequilibrium at the 0.05 level. The between-study heterogeneity was estimated using the chi-square-based Q test and quantified with the I^2^ statistic. When *P* \< 0.05 was considered the presence of significant heterogeneity among studies, the random-effects model (DerSimonian-Laird method) would be conducted. In addition, the pooled OR was calculated using the fixed-effects model (Mantel-Haenszel method) in the absence of heterogeneity. After that, subgroup analysis was further performed by type of cancer, ethnicity and source of controls. In sensitivity analysis, each study was omitted each time and the pooled ORs with 95% CIs were recalculated to measure the stability of pooled results. Publication bias between the studies was performed using Begg\'s funnel plots and Egger\'s linear regression test and by visual inspection of the funnel plot. All *P* values were two-sided and a *P* \< 0.05 was considered statistically significant. All statistical data was carried out by Stata software (version 12.0; StataCorp LP, College Station, TX).

Trial sequential analysis {#s4_5}
-------------------------

Outcome of meta-analysis might be prone to systematic or random errors owing to repeated significance testing of accumulated data and collecting sparse data, when cumulative meta-analyses were updated with addition of new publishing studies \[[@R56], [@R60], [@R63]\]. Thus, TSA was performed to reduce the risk of type I errors and confirmed more statistical reliability of the data by estimation of required information size with an adjusted threshold for statistical significance \[[@R57], [@R58]\]. In the current meta-analysis, TSA was performed with a desire to maintain a 95% confidence intervals, a 20% relative risk reduction, an overall 5% risk a type I error and a statistical test power of 80% (20% risk of the type II error), which meant that the required information size was calculated and the trial sequential monitoring boundaries was constructed. When the cumulative Z-curve (the blue line) crossed the trial sequential monitoring boundary (sloping red line) or exceeded the required information size (vertical red line), a sufficient level of evidence might have been reached and no further studies were needed. Otherwise, if the blue line did not cross any of the boundaries and the vertical red line has not been reached, additional clinical trials are needed to obtain sufficient evidence by reaching the adequate required information size \[[@R59]--[@R60], [@R64]\]. The trial sequential analysis software (TSA, version 0.9; Copenhagen Trial Unit, Copenhagen, Denmark, 2011) was carried out in this study.

CONCLUSIONS {#s5}
===========

This current meta-analysis provided statistical evidence supporting that the PSCA rs2294008 C\>T and rs2976392 G\>A polymorphisms increased the risk of cancer, especially in gastric cancer and bladder cancer. Therefore, the PSCA s2294008 C\>T and rs2976392 G\>A polymorphisms might be considered an ideal marker in the prediction of cancer in the subsequent studies. Nevertheless, more well-designed studies need to be further checked with a sufficiently large number of participants to substantiate these real associations.
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